Triple therapy plus HIFU for high-tumor-burden prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of hormone therapy, chemotherapy (docetaxel), and a targeted drug (apalutamide) with a focused ultrasound procedure (HIFU) for men with prostate cancer that has spread to many bones or organs. It may help control the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to at least 4 bones (with at least one outside your pelvis or spine) or to internal organs.
- You are newly diagnosed or your cancer came back after local treatment, and it still responds to hormone therapy.
- You have not had chemotherapy, immunotherapy, or certain advanced hormone drugs like apalutamide or enzalutamide before.
- You are able to start treatment with docetaxel, apalutamide, and hormone therapy as planned.
- You are in good general health (ECOG score 0-1), with adequate blood cell counts, liver and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment that uses high-intensity focused ultrasound to target and destroy cancer cells in the prostate, combined with a newer hormone therapy. This approach may help control advanced prostate cancer and improve outcomes.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
This trial studies a focused ultrasound treatment called HIFU for prostate cancer that appears limited to the early stages. It aims to treat cancer within the prostate while avoiding treatment spread to lymph nodes or distant organs.
This trial tests a combination of high-dose testosterone with enzalutamide and difluoromethylornithine (DFMO) for men whose prostate cancer has spread and stopped responding to standard hormone therapy. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs given before surgery for locally advanced prostate cancer. The goal is to see if giving these drugs first helps shrink the tumor and improves outcomes after surgery.
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.